NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis $1.72 +0.05 (+2.69%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.74 +0.02 (+1.17%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Curis Stock (NASDAQ:CRIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Curis alerts:Sign Up Key Stats Today's Range$1.65▼$1.7550-Day Range$1.60▼$2.8052-Week Range$1.02▼$8.29Volume56,510 shsAverage Volume111,869 shsMarket Capitalization$17.94 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingBuy Company Overview Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Read More Curis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCRIS MarketRank™: Curis scored higher than 44% of companies evaluated by MarketBeat, and ranked 626th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCuris has only been the subject of 1 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($7.12) to ($3.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.02% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 91.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.02% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 91.83%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.32 News SentimentCuris has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Curis this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Curis to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.45% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Stock News HeadlinesShort Interest in Curis, Inc. (NASDAQ:CRIS) Rises By 91.8%August 8 at 2:27 AM | americanbankingnews.comQ2 2025 Curis Inc Earnings Call TranscriptAugust 6 at 10:01 AM | gurufocus.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 8 at 2:00 AM | Weiss Ratings (Ad)Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesAugust 6 at 10:01 AM | gurufocus.comCuris, Inc. Reports Q2 2025 Financial and Clinical ProgressAugust 5 at 12:18 AM | tipranks.comCuris (CRIS) Q2 Loss Narrows 66%August 5 at 7:00 PM | fool.comCuris Inc: Promising Financial Performance and Clinical Advancements Justify Buy RatingAugust 5 at 12:42 PM | tipranks.comCuris, Inc. (CRIS) Q2 2025 Earnings Call TranscriptAugust 5 at 12:12 PM | seekingalpha.comSee More Headlines CRIS Stock Analysis - Frequently Asked Questions How have CRIS shares performed this year? Curis' stock was trading at $3.06 at the start of the year. Since then, CRIS shares have decreased by 44.0% and is now trading at $1.7150. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings data on Tuesday, August, 5th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($1.99) by $1.31. The biotechnology company had revenue of $2.75 million for the quarter, compared to analyst estimates of $2.64 million. Read the conference call transcript. When did Curis' stock split? Curis shares reverse split before market open on Friday, September 29th 2023.The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/05/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees60Year Founded2000Price Target and Rating Average Price Target for Curis$17.00 High Price Target$17.00 Low Price Target$17.00 Potential Upside/Downside+891.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($6.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.39 million Net Margins-341.24% Pretax Margin-341.24% Return on EquityN/A Return on Assets-102.22% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio1.23 Sales & Book Value Annual Sales$10.91 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.12) per share Price / Book-1.53Miscellaneous Outstanding Shares12,500,000Free Float9,892,000Market Cap$21.44 million OptionableNo Data Beta3.66 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CRIS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.